Literature DB >> 35915056

One session treatment (OST) is equivalent to multi-session cognitive behavioral therapy (CBT) in children with specific phobias (ASPECT): results from a national non-inferiority randomized controlled trial.

Barry Wright1, Lucy Tindall1, Alexander J Scott2, Ellen Lee3, Cindy Cooper3, Katie Biggs3, Penny Bee4, Han-I Wang5, Lina Gega5, Emily Hayward1, Kiera Solaiman3, M Dawn Teare2, Thompson Davis6, Jon Wilson7, Karina Lovell4, Dean McMillan5, Amy Barr3, Hannah Edwards1, Jennifer Lomas3, Chris Turtle3, Steve Parrott5, Catarina Teige1, Tim Chater3, Rebecca Hargate1, Shezhad Ali5, Sarah Parkinson1, Simon Gilbody5, David Marshall5.   

Abstract

BACKGROUND: 5%-10% children and young people (CYP) experience specific phobias that impact daily functioning. Cognitive Behaviour Therapy (CBT) is recommended but has limitations. One Session Treatment (OST), a briefer alternative incorporating CBT principles, has demonstrated efficacy. The Alleviating Specific Phobias Experienced by Children Trial (ASPECT) investigated the non-inferiority of OST compared to multi-session CBT for treating specific phobias in CYP.
METHODS: ASPECT was a pragmatic, multi-center, non-inferiority randomized controlled trial in 26 CAMHS sites, three voluntary agency services, and one university-based CYP well-being service. CYP aged 7-16 years with specific phobia were randomized to receive OST or CBT. Clinical non-inferiority and a nested cost-effectiveness evaluation was assessed 6-months post-randomization using the Behavioural Avoidance Task (BAT). Secondary outcome measures included the Anxiety Disorder Interview Schedule, Child Anxiety Impact Scale, Revised Children's Anxiety Depression Scale, goal-based outcome measure, and EQ-5DY and CHU-9D, collected blind at baseline and six-months.
RESULTS: 268 CYPs were randomized to OST (n = 134) or CBT (n = 134). Mean BAT scores at 6 months were similar across groups in both intention-to-treat (ITT) and per-protocol (PP) populations (CBT: 7.1 (ITT, n = 76), 7.4 (PP, n = 57), OST: 7.4 (ITT, n = 73), 7.6 (PP, n = 56), on the standardized scale-adjusted mean difference for CBT compared to OST -0.123, 95% CI -0.449 to 0.202 (ITT), mean difference -0.204, 95% CI -0.579 to 0.171 (PP)). These findings were wholly below the standardized non-inferiority limit of 0.4, suggesting that OST is non-inferior to CBT. No between-group differences were found on secondary outcomes. OST marginally decreased mean service use costs and maintained similar mean Quality Adjusted Life Years compared to CBT.
CONCLUSIONS: One Session Treatment has similar clinical effectiveness to CBT for specific phobias in CYP and may be a cost-saving alternative.
© 2022 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for Child and Adolescent Mental Health.

Entities:  

Keywords:  Specific phobia; children and young people; cognitive behavioral therapy; non-inferiority; one session treatment; randomized controlled trial

Year:  2022        PMID: 35915056     DOI: 10.1111/jcpp.13665

Source DB:  PubMed          Journal:  J Child Psychol Psychiatry        ISSN: 0021-9630            Impact factor:   8.265


  2 in total

1.  One-session treatment for specific phobias: Barriers, facilitators and acceptability as perceived by children & young people, parents, and clinicians.

Authors:  Emily Hayward; Kiera Solaiman; Penny Bee; Amy Barr; Hannah Edwards; Jennifer Lomas; Lucy Tindall; Alexander J Scott; Katie Biggs; Barry Wright
Journal:  PLoS One       Date:  2022-09-15       Impact factor: 3.752

2.  Cost and effectiveness of one session treatment (OST) for children and young people with specific phobias compared to multi-session cognitive behavioural therapy (CBT): results from a randomised controlled trial.

Authors:  Han-I Wang; Barry Wright; Lucy Tindall; Cindy Cooper; Katie Biggs; Ellen Lee; M Dawn Teare; Lina Gega; Alexander J Scott; Emily Hayward; Kiera Solaiman; Thompson Davis; Dean McMillan; Simon Gilbody; Steve Parrott
Journal:  BMC Psychiatry       Date:  2022-08-12       Impact factor: 4.144

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.